YumanityLogo.jpg
Yumanity Therapeutics’ YTX-7739 Demonstrates Prevention of Motor Function Deficits in a Parkinson’s Disease Mouse Model
March 09, 2021 08:00 ET | Yumanity Therapeutics Inc
YTX-7739 demonstrates pharmacological, physiological, and behavioral pre-clinical proof of concept in in vivo model Study presented at AD/PD™ 2021 BOSTON, March 09, 2021 (GLOBE NEWSWIRE) --...
YumanityLogo.jpg
Yumanity Therapeutics to Present at the H.C. Wainwright Global Life Sciences Conference
March 02, 2021 16:05 ET | Yumanity Therapeutics Inc
BOSTON, March 02, 2021 (GLOBE NEWSWIRE) -- Yumanity Therapeutics (Nasdaq: YMTX), a clinical-stage biopharmaceutical company focused on the discovery and development of innovative, disease-modifying...
YumanityLogo.jpg
Yumanity Therapeutics Provides Update on Its Lead Parkinson’s Disease Clinical Program, YTX-7739
February 10, 2021 08:00 ET | Yumanity Therapeutics Inc
Results reported of the single ascending dose study in healthy volunteers Enrollment completed of the multiple ascending dose study in healthy volunteers; results expected by end of Q1 2021 ...
YumanityLogo.jpg
Yumanity Therapeutics to Present at the H.C. Wainwright Virtual BioConnect Conference
January 06, 2021 08:00 ET | Yumanity Therapeutics Inc
BOSTON, Jan. 06, 2021 (GLOBE NEWSWIRE) -- Yumanity Therapeutics (Nasdaq: YMTX), a clinical-stage biopharmaceutical company focused on the discovery and development of innovative, disease-modifying...
YumanityLogo.jpg
Yumanity Therapeutics Completes Reverse Merger with Proteostasis Therapeutics
December 23, 2020 09:24 ET | Yumanity Therapeutics Inc
Shares of Yumanity to commence trading on Nasdaq under new ticker symbol “YMTX” on December 23, 2020 $33.6 million common stock private investment in public equity (“PIPE”) transaction closes...
YumanityLogo.jpg
Yumanity Therapeutics to Raise $33.6 Million PIPE Contingent on Completion of Reverse Merger with Proteostasis Leading institutional investors commit $33.6 million through a common stock private investment in public equity (“PIPE”) led by Fidelity Management & Research Company, LLC and Invus Proteostasis...
YumanityLogo.jpg
Yumanity Therapeutics to Present at the Piper Sandler 32nd Annual Virtual Healthcare Conference
November 24, 2020 16:30 ET | Yumanity Therapeutics
BOSTON, Nov. 24, 2020 (GLOBE NEWSWIRE) -- Yumanity Therapeutics, a clinical-stage biopharmaceutical company focused on the discovery and development of innovative, disease-modifying therapies for...
YumanityLogo.jpg
Yumanity Therapeutics to Present at the Stifel 2020 Virtual Healthcare Conference
November 10, 2020 16:30 ET | Yumanity Therapeutics
CAMBRIDGE, Mass., Nov. 10, 2020 (GLOBE NEWSWIRE) -- Yumanity Therapeutics, a clinical-stage biopharmaceutical company focused on the discovery and development of innovative, disease-modifying...
YumanityLogo.jpg
Yumanity Therapeutics Appoints Ellen K. Forest as Chief Human Resources Officer
August 03, 2020 08:00 ET | Yumanity Therapeutics
CAMBRIDGE, Mass., Aug. 03, 2020 (GLOBE NEWSWIRE) -- Yumanity Therapeutics, a clinical-stage biopharmaceutical company focused on the discovery and development of innovative, disease-modifying...
Yumanity.jpg
Yumanity Therapeutics Announces Strategic Research Collaboration and License Agreement with Merck Focused on Accelerating the Development of New Treatments for Neurodegenerative Diseases
June 24, 2020 07:00 ET | Yumanity Therapeutics
Strategic Alliance Combines Yumanity’s Innovative Drug Discovery Platform with Merck’s Development and Commercialization Expertise in Neuroscience  Merck Gains Exclusive Rights to Two Novel Yumanity...